|DB00109||Enfuvirtide||Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS.|
|DB04933||Eritoran||Investigated for use/treatment in sepsis and septicemia.|
|DB05006||Adecatumumab||Investigated for use/treatment in breast cancer and prostate cancer.|
|DB05299||keyhole limpet hemocyanin||Investigated for use/treatment in bladder cancer and solid tumors.|
|DB05413||Tifuvirtide||Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections and HIV infection.|
|DB05793||PRO-542||Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications.|
|DB05942||GI-5005||Investigated for use/treatment in hepatitis (viral, C).|
|DB06447||E5531||Investigated for use/treatment in sepsis and septicemia.|
|DB06495||Onercept||Investigated for use/treatment in psoriasis and psoriatic disorders and crohn's disease.|
|DB06611||Pegsunercept||Investigated for use/treatment in rheumatoid arthritis.|
|DB11253||Xanthan gum||Not Available|
|DB11601||Tuberculin Purified Protein Derivative||Indicated as a diagnostic agent in Mantoux Test used to detect infection with *Mycobacterium tuberculosis*. |
|DB13889||Meningococcal polysaccharide vaccine group A||Not Available|
|DB13890||Meningococcal polysaccharide vaccine group C||Not Available|
|DB11627||Hepatitis B Vaccine (Recombinant)||Active immunization against hepatitis B virus infection.
The vaccine will not protect against infection caused by hepatitis A and non-A non-B hepatitis viruses. As hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection or carrier state, it can be expected that hepatitis D will also be prevented by vaccination with hepatitis B virus vaccine.
The vaccine can be administered at any age from birth onwards. It may be used to start a primary course of vaccination or as a booster dose. It may also be used to complete a primary course of vaccination started with plasma-derived or yeast-derived vaccines or as a booster dose in subjects who have previously received a primary course of vaccination with plasma-derived or yeast-derived vaccines.
In areas of low prevalence of hepatitis B, vaccination is strongly recommended in subjects who are at increased risk of infection. These include the following groups:
* Health professionals: physicians and surgeons; oral surgeons and dentists; nurses, dental nurses, dental hygienists, podiatrists; IV teams and operating room personnel; paramedical personnel in close contact with patients; staff in hemodialysis, nephrology, hepatology, hematology and oncology units; laboratory personnel handling blood and other clinical specimens; blood bank and plasma fractionation workers; pathologists and morgue attendants; cleaning staff who handle waste in hospitals; emergency and first aid workers; ambulance staff; dental, medical and nursing students.
* Patients: patients receiving frequent blood transfusion or clotting factor concentrates, such as those in oncology units and those with thalassemia, sickle-cell anemia, cirrhosis, hemophilia, etc.; patients on hemodialysis; patients with type 2 diabetes.
* Personnel and residents of institutions: persons with frequent and/or close contacts with high-risk groups; prisoners and prison staff; residents and staff of institutions for the developmentally challenged (those who are in contact with aggressive biting residents being at highest risk).
* Persons at increased risk due to their sexual practices: males having sexual contact with other males; others with multiple sexual partners or with a recent history of sexually transmitted disease.
* Persons who use injectable drugs illicitly.
* Travellers to areas of high endemicity and their close contacts.
* Household contacts of any of the above groups and of patients with acute or chronic hepatitis B infection.
* Infants born of HBsAg-positive mothers.
* Chronic Liver Disease (CLD): subjects with chronic liver disease; subjects at risk of developing CLD (e.g. Hepatitis C virus carriers, persons who abuse alcohol).
* Others: police; fire fighters; armed forces personnel; morticians and embalmers; those who through their work or personal lifestyle may be exposed to the hepatitis B virus.
* In areas of both low and high prevalence, vaccination should be offered to all young children and neonates at risk, as well as to adult high risk groups.|
|DB15015||Recombinant CD40-ligand||Not Available|
|DB15081||Melanoma antigen recognized by T-cells 1||Not Available|